Compare TIPT & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | SANA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.9M | 793.1M |
| IPO Year | 2017 | 2021 |
| Metric | TIPT | SANA |
|---|---|---|
| Price | $17.52 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.80 |
| AVG Volume (30 Days) | 249.3K | ★ 3.8M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $488,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.49 | $2.60 |
| 52 Week High | $27.38 | $6.55 |
| Indicator | TIPT | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 59.13 |
| Support Level | $17.19 | $3.01 |
| Resistance Level | $17.56 | $3.41 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 19.21 | 76.06 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.